Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-Augmentation With GM-CSF and Pneumococcal Vaccine in CLL
NCT00323557Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2004
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in pneumococcal infection, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2004; status: completed.
02
Drugs
sargramostim
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00323557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00323557.